glp-1 receptor agonist and dpp-4 inhibitor combination not recommended Table 2 from DPP- 4 Inhibitors in the Management of Type 2 Diabetes Mellitus do not combine dpp-4 inhibitors
Description
DPP4i have a favourable therapeutic profile and are proven not to increase cardiovascular risk

J., Vlund, A

Obesity (Silver Spring) 2015;23(6):11191129

Wharton S, Davies M, Dicker D, et al

Competing interests J.O

Mehan, S
